Physician profile

Alex Cole

Gulfport, MS

NPI 1801590708

$163.91

in general payments reported to CMS, 2019-2025

7 companies · $100 in 2025

The $100 reported for 2025 was less than what a typical provider received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$163.91

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Amgen INC. $34.48 2024 Otezla, Prolia, Evenity
Abbvie INC. $32.60 2025
Ucb, INC. $25.26 2025 Fintepla
Teleflex LLC $21.65 2025 Arrow
Antares Pharma, INC. $20.83 2025 Xyosted
Ibsa Pharma INC. $14.63 2024 Licart, Tirosint
Glaxosmithkline, LLC. $14.46 2024 Arexvy, Shingrix, Fluarix Quadrivalent

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Alex Cole

$163.91

in general payments reported 2019-2025

Years
2024-2025
Top company
Amgen INC.
Context
The $100 reported for 2025 was less than what a typical provider received nationally.

https://glasscript.com/doctor/11686850/alex-cole

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.